Onco-Innovations Limited ONNVF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -66.67% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -66.67% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -66.67% | -- | -- | -- |
| SG&A Expenses | 135.06% | -24.88% | 51.27% | 1,948.26% | 340.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.88% | -8.57% | 61.12% | 1,848.08% | 449.26% |
| Operating Income | -139.58% | 5.53% | -61.12% | -1,806.09% | -436.19% |
| Income Before Tax | -24.27% | 67.33% | -31.13% | -1,862.67% | -734.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.27% | 67.33% | -31.13% | -1,862.67% | -734.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.27% | 67.33% | -31.13% | -1,862.67% | -734.10% |
| EBIT | -139.58% | 5.53% | -61.12% | -1,806.09% | -436.19% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -8.70% | 72.70% | 7.84% | -1,268.57% | -433.33% |
| Normalized Basic EPS | -8.70% | 33.53% | 9.02% | -1,259.09% | -945.45% |
| EPS Diluted | -8.70% | 72.70% | 7.84% | -1,268.57% | -433.33% |
| Normalized Diluted EPS | -8.70% | 33.53% | 9.02% | -1,259.09% | -945.45% |
| Average Basic Shares Outstanding | 14.12% | 19.61% | 42.39% | 41.54% | 56.27% |
| Average Diluted Shares Outstanding | 14.12% | 19.61% | 42.39% | 41.54% | 56.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |